Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that integrates the delivery of insulin with continuous glucose monitoring (CGM) into a compact pump.
Through this device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin, aiming to minimise the daily therapy load.
The wearable will leverage PharmaSens’ patented platform technologies along with the biosensor capabilities of SiBionics.
Both companies will offer their engineering and development know-how to bring this patch pump to the market.
PharmaSens CEO Marcel Both said: 鈥淭his partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system.
鈥淪iBionics鈥� proven expertise in sensor technology is a perfect complement to our platform.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPharmaSens is currently developing a portfolio of three insulin patch pumps, including niia signature, designed to cater to a broad range of user needs.
The range begins with the niia essential, a basal-bolus insulin pump that prioritises ease of use by minimising complexity.
The niia advanced provides additional options and can be controlled through a smartphone, also allowing connection to an external CGM.
PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin reservoir to extend wear time and reduce insulin waste.
The company is focused on simplifying diabetes management and expanding access to insulin pump therapy.
Founded in 2015, CGM technology provider SiBionics brings to the partnership its core expertise in medical device research and development, with offices in China and the US.
Last year, PharmaSens submitted an application to the US Food and Drug Administration (FDA) for approval of its niia essential insulin patch pump system.
